Sihuan’s Bireociclib Wins First-Line Breast Cancer Approval, Extending Lead in China

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an update.

Sihuan Pharmaceutical said its independently developed CDK2/4/6 inhibitor Bireociclib (Xuanyuening) has received Chinese marketing approval for a third indication, as a first-line treatment when combined with aromatase inhibitors for HR+/HER2- advanced breast cancer. With prior approvals for use with fulvestrant and as monotherapy in later lines, the drug now covers the full treatment spectrum for this subtype, which dominates China’s breast cancer cases and underpins a fast-growing CDK4/6 inhibitor market.

The latest approval is supported by Phase III BRIGHT-3 data showing a substantial reduction in disease progression or death versus endocrine therapy alone, strong response rates, and generally manageable safety, including in high-risk patients with liver metastases. As the first CDK2/4/6 inhibitor cleared in China, Bireociclib’s expanded label is expected to broaden patient coverage, enhance its clinical and commercial value, and reinforce Sihuan’s position in the competitive HR+/HER2- advanced breast cancer segment.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group is a Chinese biopharmaceutical company focused on innovative oncology treatments, operating through subsidiaries including Xuanzhu Biopharmaceutical. The group develops and commercializes novel targeted therapies, particularly in breast cancer, aiming at large unmet needs in the domestic market.

Average Trading Volume: 31,331,761

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$13.72B

For an in-depth examination of 0460 stock, go to TipRanks’ Overview page.